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Background
Treatment of chronic urticaria consists of antihistamines
as the first-line treatment. For more severe symptoms,
combinations can be necessary as well as dose augmenta-
tions. The recent guidelines suggest the possibility of using
omalizumab in resistant cases. We treated 2 patients with
cold-urticaria (CO), 1 with cholinergic urticaria(CH) and
11 with chronic spontaneous urticaria (CSU) with omali-
zumab, who had not benefited from the recommended
first-line, second-line and third-line treatments.
Methods
Patients were required to document their CU symptoms
once daily with urticaria activity scores for 7 days (7UAS).
Briefly, the symptoms were monitored in terms of numbers
of wheals [none (=0 points), <10 (=1 point), 10–50 (=2
points), or >50 per day (=3 points)], and the intensity of
their pruritus [none (=0 points), mild (=1 point), moderate
(=2 points), severe (=3 points)], for a total of 42 points. To
evaluate the efficacy of the omalizumab treatment, 7UAS
obtained at baseline was compared to that at the third and
sixth month of the therapy. Omalizumab was given at
150ug/month irrespective of IgE levels and increased to
300 mg if needed (no response). The concomitant medica-
tion was slowly reduced according to clinical response.
Results
The 7UAS improved significantly in all severe urticaria
patients with omalizumab as early as one month (not
shown) after initiation of therapy and was sustained for the
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6 month observation (Figure 1). 7UAS in patient #8 was
>30 previously but =0 at entry because treated with oral
prednisone for >1year. The response was not satisfactory
for patient # 10 and omalizumab increased to 300mg after
6 months with a better clinical response (not shown).
Along with the clinical improvement, the concomitant
medications could also be reduced significantly in all
patients except #10, particularly prednisone.
Conclusion
Our results show that omalizumab improves significantly
recommended treatment-resistant urticaria patients
(13/14) in terms of clinical symptomatology (7UAS) and
drug reduction in a real life setting. None of the patients
reported any adverse effect.
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